In Drug discovery today ; h5-index 68.0
Drug development has become unbearably slow and expensive. A key underlying problem is the clinical prediction challenge: the inability to predict which drug candidates will be safe in the human body and for whom. Dramatic regulatory changes are now in motion, seeking to remove the mandated reliance on antiquated, ineffective animal studies. A new frontier is an integration of several disruptive technologies [machine learning (ML), patient-on-chip, real-time sensing, and stem cells], which when integrated, have the potential to address this challenge, drastically cutting the time and cost of developing drugs, and tailoring them to individual patients.
Bentwich Isaac
2023-Jan-31
artificial intelligence, organ-on-chip, organoids, prediction, real-time sensing
